Skip to main content
Journal cover image

FDG-PET/CT and Pathology in Newly Diagnosed Head and Neck Cancer: ACRIN 6685 Trial, FDG-PET/CT cN0.

Publication ,  Journal Article
Stack, BC; Duan, F; Subramaniam, RM; Romanoff, J; Sicks, JD; Bartel, T; Chen, C; Lowe, VJ
Published in: Otolaryngol Head Neck Surg
June 2021

OBJECTIVE: FDG-PET/CT (fluorodeoxyglucose-positron emission tomography/computed tomography) is effective to assess for occult neck nodal disease. We report risks and patterns of nodal disease based on primary site and nodal level from data on the dissected cN0 per the results from ACRIN 6685. STUDY DESIGN: Prospective nonrandomized enrollment included participants with first-time head and neck squamous cell carcinoma and at least 1 cN0 neck side to be dissected. SETTING: Twenty-four ACRIN-certified centers internationally (American College of Radiology Imaging Network). METHODS: A total of 287 participants were enrolled. Preoperative FDG-PET/CT findings were centrally reviewed and compared with pathology. Incidence, relative risk, pattern of lymph node involvement, and impact upon neck dissection were reported. RESULTS: An overall 983 nodal levels were dissected (n = 261 necks, n = 203 participants). The highest percentages of ipsilateral positive nodes by primary location and nodal level were oral cavity (level I, 17/110, 15.5%), pharynx (level II, 6/30, 20.0%), and larynx (level VI, 1/3, 33.3%). CONCLUSION: Levels at greatest risk for nodal disease in cN0 in terms of ipsilateral neck dissection are level I (oral cavity), II (pharynx), and VI (larynx). These data should be considered when treating patients presenting with cN0. This is the first study to comprehensively report the incidence, location, and risk of metastases in cN0 in the FDG-PET/CT era.

Duke Scholars

Published In

Otolaryngol Head Neck Surg

DOI

EISSN

1097-6817

Publication Date

June 2021

Volume

164

Issue

6

Start / End Page

1230 / 1239

Location

England

Related Subject Headings

  • Young Adult
  • Radiopharmaceuticals
  • Prospective Studies
  • Positron Emission Tomography Computed Tomography
  • Otorhinolaryngology
  • Neoplasm Metastasis
  • Middle Aged
  • Male
  • Humans
  • Head and Neck Neoplasms
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Stack, B. C., Duan, F., Subramaniam, R. M., Romanoff, J., Sicks, J. D., Bartel, T., … Lowe, V. J. (2021). FDG-PET/CT and Pathology in Newly Diagnosed Head and Neck Cancer: ACRIN 6685 Trial, FDG-PET/CT cN0. Otolaryngol Head Neck Surg, 164(6), 1230–1239. https://doi.org/10.1177/0194599820969104
Stack, Brendan C., Fenghai Duan, Rathan M. Subramaniam, Justin Romanoff, JoRean D. Sicks, Twyla Bartel, Chien Chen, and Val J. Lowe. “FDG-PET/CT and Pathology in Newly Diagnosed Head and Neck Cancer: ACRIN 6685 Trial, FDG-PET/CT cN0.Otolaryngol Head Neck Surg 164, no. 6 (June 2021): 1230–39. https://doi.org/10.1177/0194599820969104.
Stack BC, Duan F, Subramaniam RM, Romanoff J, Sicks JD, Bartel T, et al. FDG-PET/CT and Pathology in Newly Diagnosed Head and Neck Cancer: ACRIN 6685 Trial, FDG-PET/CT cN0. Otolaryngol Head Neck Surg. 2021 Jun;164(6):1230–9.
Stack, Brendan C., et al. “FDG-PET/CT and Pathology in Newly Diagnosed Head and Neck Cancer: ACRIN 6685 Trial, FDG-PET/CT cN0.Otolaryngol Head Neck Surg, vol. 164, no. 6, June 2021, pp. 1230–39. Pubmed, doi:10.1177/0194599820969104.
Stack BC, Duan F, Subramaniam RM, Romanoff J, Sicks JD, Bartel T, Chen C, Lowe VJ. FDG-PET/CT and Pathology in Newly Diagnosed Head and Neck Cancer: ACRIN 6685 Trial, FDG-PET/CT cN0. Otolaryngol Head Neck Surg. 2021 Jun;164(6):1230–1239.
Journal cover image

Published In

Otolaryngol Head Neck Surg

DOI

EISSN

1097-6817

Publication Date

June 2021

Volume

164

Issue

6

Start / End Page

1230 / 1239

Location

England

Related Subject Headings

  • Young Adult
  • Radiopharmaceuticals
  • Prospective Studies
  • Positron Emission Tomography Computed Tomography
  • Otorhinolaryngology
  • Neoplasm Metastasis
  • Middle Aged
  • Male
  • Humans
  • Head and Neck Neoplasms